KORU Medical Systems Set to Release Q4 2025 Earnings on March 12

KORU Medical Systems (NASDAQ: KRMD) is anticipated to release its financial results for the fourth quarter of 2025 after the market closes on March 12, 2026. Analysts project that the company will report a loss of $0.02 per share, alongside revenues of approximately $10.90 million for the quarter. Investors and analysts can access the details during the earnings call scheduled for 4:30 PM ET.

Current Stock Performance

On Tuesday, shares of KORU Medical Systems opened at $4.61. The company exhibits a current ratio of 2.48 and a quick ratio of 1.92, indicating a solid liquidity position. Its debt-to-equity ratio stands at a minimal 0.01. Over the past year, the stock has fluctuated significantly, with a 12-month low of $1.86 and a high of $6.61. The 50-day moving average is $5.21, while the 200-day moving average is $4.80. Currently, KORU Medical Systems holds a market capitalization of approximately $213.54 million and a price-to-earnings (P/E) ratio of -57.63, reflecting a challenging earnings environment. The stock has a beta of 0.47, indicating lower volatility compared to the broader market.

Institutional Activity and Market Sentiment

Recent trading activity has seen notable changes in institutional positions regarding KORU Medical Systems. BNP Paribas Financial Markets increased its holdings in the company by 52.1% during the third quarter, now owning 10,148 shares valued at approximately $39,000. Other institutions, including Lazard Asset Management LLC and Occudo Quantitative Strategies LP, have also acquired new stakes in the company, valued at around $59,000 and $127,000, respectively. As of now, institutional investors and hedge funds collectively own 58.60% of KORU Medical Systems’ stock, reflecting a strong interest from larger financial players.

KORU Medical Systems specializes in the development and manufacture of medical devices and supplies. The company’s product lineup includes the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, and HIgH-Flo subcutaneous safety needle sets, aimed at delivering essential therapies to patients with chronic conditions such as primary immunodeficiency diseases and chronic inflammatory demyelinating polyneuropathy.

Investors will be keenly watching the upcoming earnings report for insights into KORU Medical Systems’ performance and future direction in a competitive healthcare market.